Furthermore, even though NCK is effective in combination therapies, it exhibits relatively potent single agent activity and hence could be of utility in patients with specific molecular or mutational indications, such as cancers with a high BAD phosphorylation ratio or mutations of the PI3K/AKT pathway. Here, AKT1 is linked to cancer.